Cargando…
A review of Dengvaxia®: development to deployment
Dengue is the world’s most prevalent and important arboviral disease. More than 50% of the world’s population lives at daily risk of infection and it is estimated more than 95 million people a year seek medical care following infection. Severe disease can manifest as plasma leakage and potential for...
Autores principales: | Thomas, Stephen J., Yoon, In-Kyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816420/ https://www.ncbi.nlm.nih.gov/pubmed/31589551 http://dx.doi.org/10.1080/21645515.2019.1658503 |
Ejemplares similares
-
Projected costs associated with school-based screening to inform deployment of Dengvaxia: Vietnam as a case study
por: Turner, Hugo C, et al.
Publicado: (2018) -
Dengvaxia: the world’s first vaccine for prevention of secondary dengue
por: Tully, Danielle, et al.
Publicado: (2021) -
Dengvaxia controversy: impact on vaccine hesitancy
por: Fatima, Khunsha, et al.
Publicado: (2018) -
Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?
por: Galula, Jedhan Ucat, et al.
Publicado: (2019) -
Estimating the proportion of vaccine-induced hospitalized dengue cases among Dengvaxia vaccinees in the Philippines
por: Flasche, Stefan, et al.
Publicado: (2019)